Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis

Abstract

The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.

Dependencies are inferred from the claim text.